Abstract 2916
Background
The SENECA trial showed similar progression free survival (PFS) and overall survival (OS) in non-squamous non-small cell lung cancer (nsNSCLC) patients (pts) treated with second-line docetaxel/nintedanib, regardless relapsing-time from end of first-line chemotherapy and docetaxel schedule employed (weekly or q3wks) [presented at AIOM 2018]. Because of the lack of data about optimal therapeutic algorithms for nsNSCLC pts and the evidence of a strong biologic rationale for using both antiangiogenic drugs and immunotherapy (IT), aim of the present analysis is to investigate post progression survival of SENECA pts, exploring if third-line IT may be positively influenced from prior nintedanib use.
Methods
SENECA enrolled 212 nsNSCLC pts treated with docetaxel and oral nintedanib, with the possibility of maintenance in case of stabilization or response. This evaluation focus on those 64 pts receiving a third-line treatment and aims to compare who underwent IT with the remaining ones. PFS2 and OS2 (time from start of docetaxel/nintedanib to progression during third-line or death, respectively) are investigated. Comparisons between Kaplan Meier curves of the two groups are made with Log Rank test. Hazard Ratios (HR) with 95% Confidence Interval (95%CI) are also reported.
Results
Pts treated with third-line (39 with IT, 25 with other agents) correspond to 30.2% of the entire study population; they were 40 males and 24 females, mainly current or former-smokers, with ECOG-performance status 0 in 79.7% of cases and average age of 62.2 years. At the cut-off date (April 29th, 2019), after 39.5 months follow-up, no significant differences appear between pts who received IT after SENECA progression and the other ones in terms of PFS2 (10.78 vs 7.91 months; HR 0.602 [95% CI 0.342-1.058], p-value=0.0821), while there are in terms of OS2 (14.33 vs 11.32 months; HR 0.537 [95% CI 0.292-0.987], p-value=0.0161).
Conclusions
Despite the small sample size, this analysis shows a higher post progression survival for nsNSCLC pts treated with docetaxel/nintedanib and third-line IT, postulating a synergism between the two regimens. Being this topic extremely attractive for development of new therapeutic algorithms, this report could be the basis for further investigations.
Clinical trial identification
EudraCT: 2014-005016-42.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Boehringer Ingelheim.
Disclosure
E. Capelletto: Advisory / Consultancy: Boehringer Ingelheim ; Advisory / Consultancy: AstraZeneca. A. Morabito: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Pfizer; Honoraria (self): MSD; Honoraria (self): BMS. F. Grossi: Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: Celgene; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Amgen. V. Scotti: Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre. D. Galetta: Honoraria (self): Boehringer Ingelheim ; Honoraria (self): Roche; Honoraria (self): MSD. S. Novello: Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: Celgene; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Takeda; Advisory / Consultancy: Pfizer; Advisory / Consultancy: AbbVie. All other authors have declared no conflicts of interest.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract